



Methylene blue as rescue therapy for COVID-19 patients who failed to respond to other therapies

Daryoush Hamidi Alamdari¹, Saied Hafizi Lottfabadi¹, Ahmad Bagheri Moghaddam¹, Mohammad Arastoo², George Koliakos³ and Bharat Bhushan⁴

¹Mashhad University of Medical Sciences, Iran

²University of Aberdeen, UK

³Aristotle University of Thessaloniki, Greece

⁴Texas Tech University Health Science Center (TTUHSC), USA

Abstract

Background: There is currently no consensus on specific pharmacological treatments for COVID-19 and there is debate about the efficacy and safety of antiviral drugs. This study verified the effect of the reduced form of Methylene blue (MB) as the last option of treatment to rescue patients who did not respond to Remdesivir, Interferon- α , and Favipiravir therapies.

Procedures: Twenty hospitalized severe COVID-19 patients (who failed to respond to Remdesivir, Interferon- α , and Favipiravir) were administered oral MB (1 mg/kg every 8 hours for two days, followed by 1mg/kg every 12 hours for the next days).

Main Finding: Eighteen patients recovered completely, and two patients did not survive. Conclusions: MB can be used in the treatment of COVID-19 patients. For the treatment of COVID-19 patients, in addition to fluid therapy and oxygen support, different types of drugs are required simultaneously, such as anti-viral agents, antibiotics, anticoagulants, immunomodulatory drugs, and antioxidants. MB possesses all of these properties along with anti-hypoxemia and anti-respiratory distress features and can therefore be included in the clinical management of COVID-19.

ClinicalTrials.gov Identifier: NCT04370288; and IRCT20191228045924N1.

Biography

Daryoush Hamidi Alamdari is a clinical Biochemist and an associate professor at the clinical Biochemistry Department, Medical School, Mashhad University of Medical Sciences, Mashhad, Iran from 2008 till the present. He has a specialty in stem cell culture and therapy. He has a specialty in fibrin glue preparation for clinical application. He has a specialty in wound treatment, vesicovaginal and anal fistula treatment, and chylothorax treatment by fibrin glue. He has published 82 articles..



12th International Conference on Clinical Case Reports
December 08, 2021

Citation: Daryoush Hamidi Alamdari, Methylene blue as rescue therapy for COVID-19 patients who failed to respond to other therapies, Clinical Case Reports 2021, 12th International Conference on Clinical Case Reports | December 08, 2021, 05